TY - JOUR
T1 - Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history
AU - Furukawa, Masashi
AU - Sou, Junichi
AU - Yamamoto, Hiromasa
AU - Ichimura, Kouichi
AU - Shien, Kazuhiko
AU - Maki, Yuho
AU - Muraoka, Takayuki
AU - Tanaka, Norimitsu
AU - Ueno, Tsuyoshi
AU - Asano, Hiroaki
AU - Tsukuda, Kazunori
AU - Toyooka, Shinichi
AU - Miyoshi, Shinichiro
PY - 2013
Y1 - 2013
N2 - Nuclear factor of k-light polypeptide gene enhancer in B cells inhibitor a (NFKBIA), which is a tumor suppressor gene, was found to be silenced in lung adenocarcinomas. We examined NFKBIA expression, mutations in the EGFR and K-ras genes, and EML4-ALK fusion in 101 resected lung adenocarcinoma samples from never-smokers. NFKBIA expression was evaluated using immunohis-tochemistry. NFKBIA expression was negative in 16 of the 101 samples (15.8%). EGFR and K-ras mutations and EML4-ALK fusion were detected in 61 (60.5%), 1 (1.0%), and 2 (2.0%) of the 101 samples, respectively, in a completely mutually exclusive manner. Negative NFKBIA expression was observed significantly more frequently among the tumors with none of the three genetic alterations compared to those with such alterations (p - 0.009). In addition, negative NFKBIA expression was significantly more frequent among the EGFR-wild type samples compared to the EGFR-mutant samples (p - 0.013). In conclusion, NFKBIA expression was silenced in adenocarcinomas without EGFR/ K-ras mutations or EML4-ALK fusion, suggesting that the silencing of NFKBIA may play an important role in the carcinogenesis of adenocarcinomas independent of EGFR/K-ras mutations or EML4-ALK fusion.
AB - Nuclear factor of k-light polypeptide gene enhancer in B cells inhibitor a (NFKBIA), which is a tumor suppressor gene, was found to be silenced in lung adenocarcinomas. We examined NFKBIA expression, mutations in the EGFR and K-ras genes, and EML4-ALK fusion in 101 resected lung adenocarcinoma samples from never-smokers. NFKBIA expression was evaluated using immunohis-tochemistry. NFKBIA expression was negative in 16 of the 101 samples (15.8%). EGFR and K-ras mutations and EML4-ALK fusion were detected in 61 (60.5%), 1 (1.0%), and 2 (2.0%) of the 101 samples, respectively, in a completely mutually exclusive manner. Negative NFKBIA expression was observed significantly more frequently among the tumors with none of the three genetic alterations compared to those with such alterations (p - 0.009). In addition, negative NFKBIA expression was significantly more frequent among the EGFR-wild type samples compared to the EGFR-mutant samples (p - 0.013). In conclusion, NFKBIA expression was silenced in adenocarcinomas without EGFR/ K-ras mutations or EML4-ALK fusion, suggesting that the silencing of NFKBIA may play an important role in the carcinogenesis of adenocarcinomas independent of EGFR/K-ras mutations or EML4-ALK fusion.
KW - Adenocarcinoma
KW - Epidermal growth factor receptor
KW - Lung cancer
KW - Never-smoker
KW - Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α
UR - http://www.scopus.com/inward/record.url?scp=84875856180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875856180&partnerID=8YFLogxK
M3 - Article
C2 - 23439505
AN - SCOPUS:84875856180
SN - 0386-300X
VL - 67
SP - 19
EP - 24
JO - Acta medica Okayama
JF - Acta medica Okayama
IS - 1
ER -